BriaCell Therapeutics raises $5.3 mln from U.S. biotech funds
Vancouver and Berkeley, California-based BriaCell Therapeutics Corp (TSX-V: BCT), an immuno-oncology-focused biotechnology company, has raised about $5.3 million in financing. According to details of a non-brokered private placement, BriaCell sold over 43 million shares of the company at $0.10 per share. In addition to this deal, BriaCell raised US$800,000 (about $1 million) in a brokered private placement. The U.S. life sciences investors included Brio Capital Master Fund, Efrat Investments and Mario Family Partners. The proceeds will be used to fund BriaCell's Phase-2a clinical trial, to pursue research opportunities, and for other priorities.
27 March 2018•6 mins read
